Intestinal Research

Original Article

IBD

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein; Intest Res 2022;20(1):72-77. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00117

Background/Aims
Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that it is more gut selective and associated with fewer side effects. The aim of this study is to assess the effect of vedolizumab compared to anti-tumor necrosis factor (anti-TNF) therapy on the perioperative complications in patients undergoing surgery for inflammatory bowel disease (IBD).
Methods
Retrospective review of patients treated for IBD at a tertiary care center between 2013 and 2017. Rates of 30- and 90-day complications for patients on vedolizumab were compared to patients on anti-TNF regimens.
Results
One hundred and ninety-nine patients met inclusion criteria with 87 (43%) patients undergoing surgery for CD, 111 (55.8%) for UC and 1 (0.5%) for indeterminate colitis. Thirty-eight patients received preoperative vedolizumab and 94 received anti-TNF. There were more males and lower body mass index in the anti-TNF group. There was no significant difference in overall rate of complications at 30 or 90 days. There was a trend for lower leak rate vedolizumab group (0% for vedolizumab vs. 2.1% for anti-TNF at 30 days, P= 1.00; 0% for vedolizumab vs. 1.1% for anti-TNF at 90 days, P= 1.00). Multivariate analysis showed low albumin ( < 3.6 g/dL) at the time of surgery to be a significant risk factor for overall and infectious complications at 90 days (odds ratio, 3.24; 95% confidence interval, 1.12–8.79; P= 0.021).
Conclusions
Perioperative vedolizumab does not increase rates of perioperative complications in IBD surgery when compared to anti-TNF medications.

Citations

Citations to this article as recorded by

Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings
Rheumatic Disease Clinics of North America.2025; 51(2): 383. CrossRef
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats
Alexandra Menni, Georgios Tzikos, Patroklos Goulas, George Chatziantoniou, Angeliki Vouchara, Athanasios S. Apostolidis, Aristeidis Ioannidis, Georgios Germanidis, Lyssimachos G. Papazoglou, Olga Giouleme, Stylianos Apostolidis
Biomedicines.2025; 13(5): 1079. CrossRef
Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
Shubha Bhat, Benjamin Click, Miguel Regueiro
Inflammatory Bowel Diseases.2024; 30(5): 829. CrossRef
Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings
Anesthesiology Clinics.2024; 42(1): 131. CrossRef
Peri-Operative Optimization of Patients with Crohn’s Disease
Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L. Cohen
Current Gastroenterology Reports.2024; 26(5): 125. CrossRef
Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
Yonsei Medical Journal.2024; 65(7): 380. CrossRef
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
Gabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, Fabiana Castiglione, Laura Melotti, Stefano Festa, Edoardo Vincenzo Savarino, Marie Truyens, Konstantinos Argyriou, Daniele Noviello, Tamas Molnar, Vincent Bouillon, Cristina Bezzio, Piotr Eder, Samuel
American Journal of Gastroenterology.2024; 119(8): 1525. CrossRef
Newer Immunosuppressants for Rheumatologic Disease
Ye Rin Koh, Kenneth C. Cummings
Rheumatic Disease Clinics of North America.2024; 50(3): 545. CrossRef
Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
Warren A. James, Angela L. Rosenberg, Jashin J. Wu, Sylvia Hsu, April Armstrong, Elizabeth B. Wallace, Lara Wine Lee, Joseph Merola, Sergio Schwartzman, Dafna Gladman, Clive Liu, John Koo, Jason E. Hawkes, Soumya Reddy, Ron Prussick, Paul Yamauchi, Michae
Journal of the American Academy of Dermatology.2024; 91(2): 251.e1. CrossRef
Tofacitinib Exposure Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Total Colectomy: A Retrospective Case–Control Study
Ibrahim Gomaa, Sara Aboelmaaty, Himani Bhatt, Robert A. Vierkant, Sherief F. Shawki, David W. Larson, Kevin T. Behm, Kristen K. Rumer
Diseases of the Colon & Rectum.2024; 67(11): 1443. CrossRef
An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Sailish Honap, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Expert Opinion on Drug Safety.2023; 22(9): 767. CrossRef
Perioperative Management of Pediatric Crohn’s Disease
Brad Pasternak, Ashish Patel, Paul Tran, Lisa McMahon
Journal of Pediatric Gastroenterology & Nutrition.2023; 76(2): 137. CrossRef
Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management
William J. Kane, Puja Shah Berry
Clinics in Colon and Rectal Surgery.2023; 36(03): 210. CrossRef
Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park
Intestinal Research.2022; 20(1): 1. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?
Caiguang Liu, Na Li, Shukai Zhan, Zhenyi Tian, Dongxuan Wu, Tong Li, Zhirong Zeng, Xiaojun Zhuang
Expert Opinion on Biological Therapy.2021; : 1. CrossRef

6,512 View
387 Download
14 Web of Science
16 Crossref

Case Report

IBD

A case of ulcerative colitis presenting with cerebral venous thrombosis: Junghwan Lee, Sung Wook Hwang, Jinhee Lee, Kyung Hwa Jung, Ha Il Kim, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang; Intest Res 2018;16(2):306-311. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.306

Abstract PDF PubReader ePub

Patients with inflammatory bowel disease (IBD) have been reported to have an increased risk of thromboembolism. Cerebral venous thrombosis (CVT) is a rare but serious extraintestinal manifestation of IBD. Due to its highly variable manifestation and low incidence, CVT is not usually readily recognized by physicians. Herein, we report a case of a 35-year-old male presenting with CVT associated with ulcerative colitis (UC). The patient was admitted with chief complaints of bloody diarrhea that had started 3 days prior. Sigmoidoscopy showed hyperemic and edematous mucosa, friability, and shallow ulcers from the sigmoid colon to the rectum suggestive of IBD. Three days later, the patient started complaining of a headache, and gradually developed a decreased level of consciousness. Magnetic resonance imaging of the brain revealed CVT with hemorrhagic infarctions. An angiogram was obtained to evaluate the extent of CVT, and anticoagulation therapy was initiated with intravenous heparin. During hospitalization, he was diagnosed with UC and treated with 5-aminosalicylic acid. After discharge, the patient was recovered without neurological deficit, and remission of UC was also obtained. The presence of headache or acute worsening of neurological status in a patient with IBD should alert the health professionals about the possibility of CVT.

Citations

Citations to this article as recorded by

Digit Necrosis After Hand Surgery in Pregnancy: A Case Report
Natalia Ziolkowski, Jana Dengler, Cory S Goldberg
Plastic Surgery Case Studies.2021;[Epub] CrossRef
Cerebral venous thrombosis as presenting manifestation of inflammatory bowel disease (IBD)
Katie Stamp, Alison Pattinson, Paul Maliakal, Thekootu Nandakumar, Shaji Sebastian
GastroHep.2019; 1(1): 45. CrossRef

8,120 View
103 Download
2 Web of Science
2 Crossref

Original Article

Miscellaneous

A simple phenotypic classification for celiac disease: Ajit Sood, Vandana Midha, Govind Makharia, B. K. Thelma, Shivalingappa S Halli, Varun Mehta, Ramit Mahajan, Vikram Narang, Kriti Sood, Kirandeep Kaur; Intest Res 2018;16(2):288-292. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.288

Abstract PDF PubReader ePub

<b>Background/Aims</b><br/>

Celiac disease is a global health problem. The presentation of celiac disease has unfolded over years and it is now known that it can manifest at different ages, has varied presentations, and is prone to develop complications, if not managed properly. Although the Oslo definitions provide consensus on the various terminologies used in literature, there is no phenotypic classification providing a composite diagnosis for the disease.

Methods

Various variables identified for phenotypic classification included age at diagnosis, age at onset of symptoms, clinical presentation, family history and complications. These were applied to the existing registry of 1,664 patients at Dayanand Medical College and Hospital, Ludhiana, India. In addition, age was evaluated as below 15 and below 18 years. Cross tabulations were used for the verification of the classification using the existing data. Expert opinion was sought from both international and national experts of varying fields.

Results

After empirical verification, age at diagnosis was considered appropriate in between A1 (<18) and A2 (≥18). The disease presentation has been classified into 3 types–P1 (classical), P2 (non-classical) and P3 (asymptomatic). Complications were considered as absent (C0) or present (C1). A single phenotypic classification based on these 3 characteristics, namely age at the diagnosis, clinical presentation, and intestinal complications (APC classification) was derived.

Conclusions

APC classification (age at diagnosis, presentation, complications) is a simple disease explanatory classification for patients with celiac disease aimed at providing a composite diagnosis.

Citations

Citations to this article as recorded by

Analyzing the landscape of coeliac crisis in adult and paediatric populations: A systematic review and meta-analysis
Arkadeep Dhali, Rick Maity, Hareesha Rishab Bharadwaj, Syed Hasham Ali, Muhammad Hamza Shah, David Surendran Sanders
Digestive and Liver Disease.2025; 57(6): 1149. CrossRef
Clinicopathologic Analysis of Malabsorption Syndrome in a Tertiary Care Center in South India
Nidhya Ganesan, S. Shrinnivi, R. Shivani, R. K. Kartikayan
Medical Journal of Dr. D.Y. Patil Vidyapeeth.2024; 17(3): 616. CrossRef
Prevalence of haplotype DQ2/DQ8 and celiac disease in children with type 1 diabetes
Agnieszka Zubkiewicz-Kucharska, Tatiana Jamer, Joanna Chrzanowska, Katarzyna Akutko, Tomasz Pytrus, Andrzej Stawarski, Anna Noczyńska
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
Celiac crisis, a rare occurrence in adult celiac disease: A systematic review
Daniel Vasile Balaban, Alina Dima, Ciprian Jurcut, Alina Popp, Mariana Jinga
World Journal of Clinical Cases.2019; 7(3): 311. CrossRef
The spectrum of clinical and subclinical endocrinopathies in treatment-naïve patients with celiac disease
Vipin Gupta, Alka Singh, Rajesh Khadgawat, Ashish Agarwal, Asif Iqbal, Wajiha Mehtab, P.K. Chaturvedi, Vineet Ahuja, Govind K. Makharia
Indian Journal of Gastroenterology.2019; 38(6): 518. CrossRef

6,581 View
109 Download
4 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search